Introduction
============

The debilitating nature of chronic cluster headache (CH) can negatively impact a patient\'s quality of life (QoL). In recent years, non-invasive neuromodulation devices have been of increasing interest for the treatment of CH.

Aim
===

The Prevention and Acute Treatment of Chronic Cluster Headache (PREVA) study was designed to evaluate the clinical effects---including QoL outcomes---of gammaCore®, a non-invasive vagus nerve stimulation device (nVNS), in subjects with chronic CH.

Methods
=======

PREVA was a randomized, well-controlled study comprised of a 2-week run-in phase, a 4-week randomized (1:1; nVNS vs standard of care \[SoC\]) phase, and a 4-week extension phase. Subjects delivered stimulations prophylactically twice daily (mandatory) or optionally for the rescue treatment of CH attacks. Three validated scales (EQ-5D-3L™, Headache Impact Test™ \[HIT-6\], and Hospital Anxiety and Depression Scale \[HADS\]) were used to assess the QoL of subjects at the end of each study phase.

Results
=======

A total of 97 subjects were randomized to treatment; data from 93 subjects (n=45 nVNS; n=48 SoC) were included in the efficacy analysis population. Compared with subjects treated with SoC alone, subjects also treated with nVNS reported greater overall improvements in EQ-5D-3L, HIT-6, and HADS scores from the end of run-in to the end of the randomized phase. As of June 2014, QoL data from the extension phase were not available; however, they will be available for presentation at EHMTIC.

Conclusion
==========

Compared with SoC, use of nVNS for the both preventive and acute treatment of CH was associated with greater improvement in QoL as assessed on 3 validated instruments.
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